HRP20090417T1 - Kombinacijsko liječenje multiple skleroze - Google Patents

Kombinacijsko liječenje multiple skleroze

Info

Publication number
HRP20090417T1
HRP20090417T1 HR20090417T HRP20090417T HRP20090417T1 HR P20090417 T1 HRP20090417 T1 HR P20090417T1 HR 20090417 T HR20090417 T HR 20090417T HR P20090417 T HRP20090417 T HR P20090417T HR P20090417 T1 HRP20090417 T1 HR P20090417T1
Authority
HR
Croatia
Prior art keywords
multiple sclerosis
combination treatment
combination
active ingredients
treatment
Prior art date
Application number
HR20090417T
Other languages
English (en)
Croatian (hr)
Inventor
De Luca Giampiero
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Publication of HRP20090417T1 publication Critical patent/HRP20090417T1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Electrotherapy Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Transplanting Machines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HR20090417T 2004-12-22 2005-12-20 Kombinacijsko liječenje multiple skleroze HRP20090417T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63867404P 2004-12-22 2004-12-22
EP04106910 2004-12-22
PCT/EP2005/056943 WO2006067134A1 (en) 2004-12-22 2005-12-20 Combination treatment for multiple sclerosis

Publications (1)

Publication Number Publication Date
HRP20090417T1 true HRP20090417T1 (hr) 2009-09-30

Family

ID=35789196

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20090417T HRP20090417T1 (hr) 2004-12-22 2005-12-20 Kombinacijsko liječenje multiple skleroze

Country Status (17)

Country Link
US (1) US20100129353A1 (cg-RX-API-DMAC7.html)
EP (1) EP1835922B1 (cg-RX-API-DMAC7.html)
JP (1) JP2008524310A (cg-RX-API-DMAC7.html)
AT (1) ATE431740T1 (cg-RX-API-DMAC7.html)
AU (1) AU2005318183B2 (cg-RX-API-DMAC7.html)
CA (1) CA2590471A1 (cg-RX-API-DMAC7.html)
CY (1) CY1109316T1 (cg-RX-API-DMAC7.html)
DE (1) DE602005014570D1 (cg-RX-API-DMAC7.html)
DK (1) DK1835922T3 (cg-RX-API-DMAC7.html)
ES (1) ES2325552T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20090417T1 (cg-RX-API-DMAC7.html)
IL (1) IL183924A (cg-RX-API-DMAC7.html)
NO (1) NO20073635L (cg-RX-API-DMAC7.html)
PL (1) PL1835922T3 (cg-RX-API-DMAC7.html)
PT (1) PT1835922E (cg-RX-API-DMAC7.html)
SI (1) SI1835922T1 (cg-RX-API-DMAC7.html)
WO (1) WO2006067134A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4720125A1 (en) 2023-05-30 2026-04-08 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
EP4762093A1 (en) 2023-08-14 2026-06-24 Paragon Therapeutics, Inc. Alpha 4 beta 7 integrin binding proteins and methods of use

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2521565B1 (fr) * 1982-02-17 1985-07-05 Dior Sa Parfums Christian Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees
FR2534487B1 (fr) * 1982-10-15 1988-06-10 Dior Christian Parfums Procede d'homogeneisation de dispersions de phases lamellaires lipidiques hydratees, et suspensions obtenues par ce procede
US5310732A (en) * 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US5077211A (en) * 1988-07-06 1991-12-31 Applied Genetics, Inc. Purification and administration of dna repair enzymes
GB9206318D0 (en) * 1992-03-24 1992-05-06 Cambridge Antibody Tech Binding substances
GB9015198D0 (en) * 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) * 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5871907A (en) * 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
US6225447B1 (en) * 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
ES2136092T3 (es) * 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
PT1024191E (pt) * 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5872215A (en) * 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
US5208327A (en) * 1991-12-18 1993-05-04 Ortho Pharmaceutical Corporation Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine
US5733743A (en) * 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
ATE199392T1 (de) * 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US6001809A (en) * 1994-07-11 1999-12-14 Elan Pharmaceuticals, Inc. Inhibitors of leukocyte adhesion
GB9712818D0 (en) * 1996-07-08 1997-08-20 Cambridge Antibody Tech Labelling and selection of specific binding molecules
US6194395B1 (en) * 1999-02-25 2001-02-27 Orthro-Mcneil Pharmaceutical, Inc. Cyclodextrin cladribine formulations
KR20040105740A (ko) * 2002-02-25 2004-12-16 엘란 파마슈티칼스, 인크. 염증 치료제의 투여 방법
ES2584183T3 (es) * 2003-03-28 2016-09-26 Ares Trading S.A. Formulaciones de cladribina para suministro mejorado oral y transmucosa

Also Published As

Publication number Publication date
PT1835922E (pt) 2009-07-08
AU2005318183A1 (en) 2006-06-29
WO2006067134A1 (en) 2006-06-29
IL183924A (en) 2010-11-30
ES2325552T3 (es) 2009-09-08
IL183924A0 (en) 2007-10-31
SI1835922T1 (sl) 2009-10-31
NO20073635L (no) 2007-09-24
US20100129353A1 (en) 2010-05-27
CA2590471A1 (en) 2006-06-29
DE602005014570D1 (cg-RX-API-DMAC7.html) 2009-07-02
EP1835922B1 (en) 2009-05-20
CY1109316T1 (el) 2014-07-02
AU2005318183B2 (en) 2011-03-31
ATE431740T1 (de) 2009-06-15
DK1835922T3 (da) 2009-08-03
EP1835922A1 (en) 2007-09-26
JP2008524310A (ja) 2008-07-10
PL1835922T3 (pl) 2009-10-30

Similar Documents

Publication Publication Date Title
Perissinotto et al. Involvement of chemokine receptor 4/stromal cell–derived factor 1 system during osteosarcoma tumor progression
ES2619332T3 (es) Fosfatasa alcalina dirigida al hueso, kits y métodos de uso de la misma
ATE405650T1 (de) Produktion von ganzen antikörpern in prokaryontischen zellen
ATE407204T1 (de) Zellproliferationsinhibitoren mit anti-glypican-3-antikörper
DE69635671D1 (de) Verwendung von roxithromycin zur herstellung eines medikaments zur verbesserung der biologischen und antiviralen aktivität von protease-inhibitoren
EP1809280A4 (en) MITOTIC KINESINE INHIBITORS AND METHOD OF USE THEREOF
EP1575486A4 (en) METHOD AND COMPOSITION FOR IDENTIFYING THERAPEUTIC ANTI-HIV MEDIUM
TNSN07304A1 (en) Combination of xolair with immunosuppressive agent
HRP20090003T3 (en) Oligopeptides for reducing elevated blood urea concentration
BRPI0410467A (pt) composições e métodos para tratamento de sìndrome respiratória aguda severa (sars)
EP1072273A4 (en) VASKULARISIERUNGSINHIBITOREN
TW200606177A (en) Glycoprotein VI antibodies and methods thereof
SE0202598D0 (sv) Alpha-7 Nicotinic receptor agonists and statins in combination
FI963462A0 (fi) Bentsotiofeeni-, bentsofuraani- ja indolitiatsepinonit, -oksatsepinonit ja -diatsepinonit soluadheesion estäjinä ja HIV:n estäjinä
ATE444083T1 (de) Selektives targeting von apoptotischen zellen
FR2883184B1 (fr) Composition de spirulines riche en principes actifs, procede d'obtention et utilisation
YU87501A (sh) Farmaceutski kompleksi
ATE324905T1 (de) Verwendung von plgf zur vorbeugung oder behandlung von ischaemie oder schlaganfall
CY1109316T1 (el) Συνδυαστικη αγωγη για πολλαπλη σκληρυνση
ATE392213T1 (de) Verwendung von gamma-gt inhibitoren zur behandlung von chronischen degenerativerkrankungen
WO2002088665A3 (en) Methods for identifying drugs specific for known molecular targets using model compounds specific for the molecular targets
FR2885812B1 (fr) Medicament a base de laminarine ou d'oligolaminarines pour le traitement de la septicemie et du choc septique
DE59911103D1 (de) ISOLIERTE UND GEREINIGTE HUMANE LÖSLICHE GUANYLYLCYCLASE ALPHA1/BETA1 (hsGC ALPHA1/BETA1)
Wardle Altering the course of proliferative nephritides: the challenge of the 1990s
MA29749B1 (fr) Solutions otologiques contenant des extraits de pau d'arco.